about
Weekly oral alendronate in mevalonate kinase deficiencyPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesAutoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's diseaseDiagnosis and classification of relapsing polychondritisWorking the endless puzzle of hereditary autoinflammatory disorders.Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.Biological treatments in Behçet's disease: beyond anti-TNF therapy.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Overlap connective tissue disease syndromes.Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis.The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathwayEffectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersMonogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issuesThe use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infectionBlau syndrome, clinical and genetic aspects.Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up.Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.Untangling the web of systemic autoinflammatory diseases.Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis.Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.The Definition and Measurement of Axial Psoriatic Arthritis.Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.Psoriatic arthritis and psoriasis: differential diagnosis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints.Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy.Small molecule therapy for managing moderate to severe psoriatic arthritis.PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.Dactylitis in enteropathic spondyloarthritis.
P50
Q21202850-139B2651-8D60-4979-879E-3C93777B81A3Q26777084-DDF83574-CC0D-4416-A969-EEEC49C1C611Q26778253-1FE3C5A6-2956-483E-93F3-8A93E1B31238Q28306563-DB0D10B3-A340-4224-A5DC-0486B2A28D13Q33357128-9AB09253-A54B-4369-95C4-914114CBDADDQ33387811-B0EC9187-CFAC-49C5-8664-E88ABF41F1DAQ33908217-0C8793A0-2FD3-4F46-AA48-95B1250B8B8DQ33993099-820167B1-0D02-4D3F-AC15-FE3858226AEFQ34284779-5B47F73A-279A-4475-9FEF-2794C8A82AA6Q34443117-8B441026-205F-4E8E-8DCA-268280008E21Q35559391-B22B16C2-03BD-4B3A-A61B-C690662D3FCEQ36009390-435B53EC-170B-441E-A12E-526D3B211DA6Q37077564-E60B406D-550F-4B7B-BCC8-B900430C3D0FQ37299354-E5202ECF-77A1-45E6-93E7-98E6C436E796Q37655910-B757C087-A6F9-4569-836C-354CE3B1C92DQ38033878-652B3497-C68A-4B8B-A86D-8D62F9B8A974Q38097750-71416130-79DB-436A-A1FD-7382EC56F915Q38176123-D2421A9B-8A4B-4513-8B96-08BE6366DC2BQ38202538-28F6074D-77C7-478E-B614-8F38785E6D73Q38220758-F211CE31-7D2A-40E8-A15F-F0CCED5AC0E0Q38222307-473E9E78-B10D-427E-BF9C-B146C7AB1930Q38240838-B4A80828-BDAD-4D8F-85A5-271E1965738FQ38242729-0AA01114-07B0-4999-B832-3C2DA23CA550Q38245566-F6E24ED3-F05B-459B-A909-98090D0F0222Q38344512-56F0C4CE-4902-4321-8A03-0F1FC7EFB963Q38622059-9FD12D29-6623-444B-A195-3BB9E63FF508Q38622088-618B2B6A-C49C-41A0-AEE7-1A8D14DA7C78Q38739243-8D636152-AAA8-45D6-9474-F887274A0FA7Q38828427-DD6A4BC2-8924-4DAC-85ED-5571F6263264Q38856226-2279AC8C-A73D-4BFB-B911-8E153A22EAA9Q39084926-9F4E80A2-2423-4EFE-89D5-6D61B6837152Q39282542-29EB49DF-079A-4E7F-92A1-B6A1B772F4CDQ39384426-B9B21BD5-D7B6-4D47-ADD5-941F7B4F9E09Q39748097-80335A0C-BA85-47E7-8585-E1909B29BE94Q39861020-269835E0-31F7-4E2F-8DA4-E996B331D7EEQ39929264-8C73607A-F520-47C8-8673-A8A42C8B499AQ40054188-4EBC2C08-48CB-4780-AFC2-2FB1B63912E0Q40054188-6EDAA341-3360-4CBF-88D8-3C800AEA46FBQ40170236-4E3F2B56-DCDF-4ABF-AA56-F3BB1D06A314Q40630984-2BCE42F5-5C15-4D41-90C9-7C359EB29514
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Caso
@ast
Francesco Caso
@en
Francesco Caso
@es
Francesco Caso
@fr
Francesco Caso
@nl
Francesco Caso
@sl
type
label
Francesco Caso
@ast
Francesco Caso
@en
Francesco Caso
@es
Francesco Caso
@fr
Francesco Caso
@nl
Francesco Caso
@sl
prefLabel
Francesco Caso
@ast
Francesco Caso
@en
Francesco Caso
@es
Francesco Caso
@fr
Francesco Caso
@nl
Francesco Caso
@sl
P106
P1153
26634875200
P21
P2798
P31
P496
0000-0002-8928-2520